Preclinical studies using an experimental autoimmune encephalomyelitis (EAE) model, a flawed but adequate murine model of MS, confirmed the effectiveness of Tregs in suppressing antigen-specific autoreactive immune responses [109] through a mechanism that involves IL-10 [110]. Here, IL10 is linked to myeloid sarcoma.